Particle.news
Clinical Trials Clinical Research Therapeutics Oncology Cancer Research Regulatory Affairs Antibody Therapies Cancer Therapies Research and Development Targeted Therapies Cancer Treatments Formulation Science Peptide Synthesis Non-Pharmaceutical Interventions Cytoskeletal Biology FDA Regulations Investigational Drugs Lifespan Extension Mechanism of Action Integrated Stress Response Preclinical Testing Clinical Studies Regulatory Approval Amino Acids Aesthetic Applications Innovative Therapies Antiviral Agents Nanotechnology Therapeutic Interventions Therapeutic Innovations Immunohistochemistry Clinical Production Preclinical Research Metabolic Disorders Endocannabinoid System Smart Insulin RNA Interference Rare Diseases Biosimilars Market Access Analytical Techniques Artificial Intelligence Chronic Diseases Market Trends FDA Manufacturing Veterinary Medicine Phase 2 Studies Protein Structure Prediction Biomacromolecules Advanced Therapies Anti-Cancer Drugs Autoimmune Conditions Antibody-Drug Conjugates ANAVEX®2-73 Nanoparticle Formulation Therapeutic Candidates
The deal creates a time‑limited royalty stream to BioMarin through May 2030 and removes the threat of an ITC import enforcement action.
